Better Life by Nutrition During Adulthood (BELINDA)

December 16, 2025 updated by: University Hospital, Lille

Better Life by Nutrition During Adulthood : Identification of Factors Present in Adolescence Cardiovascular Risk in Young Adults

BELINDA is a follow'up of subjects included 10 years ago in HELENA study which was a cross-sectional study carried out from 2006 to 2007 in more than 3500 adolescents aged from 12.5 to 17.5 years old through 10 Europeans towns from 9 countries.

BELINDA main objective is to assess CV risk using PDAY score (Pathobiological Determinants of Atherosclerosis in Youth) during young adulthood (20 to 31 years) and analyze lifestyle risk factors from adolescence (12 to 18 years). This analyze may define new CV risk factors and risk population cluster.

Study Overview

Status

Completed

Detailed Description

BELINDA subjects from Lille, Ghent , Zaragoza and Roma will be re-tested using a part of HELENA test battery and some new evaluation criteria.

Study Type

Observational

Enrollment (Actual)

72

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France
        • CHRU,Hôpital Jeanne de Flandres

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

BELINDA is a follow'up of subjects included 10 years ago in HELENA study which was a cross-sectional study carried out from 2006 to 2007 in more than 3500 adolescents aged from 12.5 to 17.5 years old through 10 Europeans towns from 9 countries.

BELINDA will retest subjects from Lille and Ghent

Description

Inclusion Criteria:

  • Women of men participating to HELENA study 2006-2007
  • Aged from 20 to 35 years.
  • Signed informed consent

Exclusion Criteria:

  • Pregnant or lactating women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PDAY score (Pathobiological Determinants of Atherosclerosis in Youth)
Time Frame: one day
PDAY score is a composite score which will be calculated using adult data including Gender, HDL non cholesterol, HDL cholesterol. Glucose level, Blood pressure, Tobacco consumption and BMI.
one day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diet Quality Index Score
Time Frame: 2 days

data collected using HELENA-DIAT, an electronic dietary recall, data in DQI score unit.

DQI score is ranking from 0 to 9 unit and is based on three basic principles for a healthy diet: quality; diversity; balance. Furthermore, the daily diet was divided into nine recommended food groups, namely (1) water, (2) bread and cereals, (3) grains and potatoes, (4) vegetables, (5) fruit, (6) milk products (7), cheese, (8) meat, fish, eggs and substitutes, and (9) fats and oils.

2 days
Ratio total energy intake
Time Frame: 2 days
data collected using HELENA-DIAT, an electronic dietary recall, data in kcal/d, data for recommended total energy intake will be collected using national reference chart.
2 days
ratio of dietary n-6/n-3 polyunsaturated fatty acids (PUFA)
Time Frame: 2 days
data collected using HELENA-DIAT, an electronic dietary recall, data in ratio calculated using a food composition data base. PUFA is expressed in mg/day daily intake.
2 days
consumption in dietary salt intake
Time Frame: 2 days
data collected using HELENA-DIAT, an electronic dietary recall, data in mg/day daily intake calculated using a food composition data base.
2 days
Physical activity
Time Frame: 7 days
data collected using a GT3X accelerometer data in daily counts/min
7 days
Endurance
Time Frame: 1 day
data collected using Dr Leger Shuttle run test, data in VO2max ml/kg/min
1 day
Ratio waist-to-hip
Time Frame: 1 day
data collected using anthropometric measurements, data in ratio. Data are expressed in centimeter
1 day
Fat mass
Time Frame: 1 day
data collected using anthropometric measurements, data in % of fat mass, expressed in kg
1 day
Education level
Time Frame: 1 day
data collected using a Socio-economic questionnaire, data in Education level 8 digits
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frédéric Gottrand, MD, PhD, University Hospital, Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 23, 2017

Primary Completion (Actual)

March 25, 2022

Study Completion (Actual)

March 25, 2022

Study Registration Dates

First Submitted

August 24, 2016

First Submitted That Met QC Criteria

September 8, 2016

First Posted (Estimated)

September 14, 2016

Study Record Updates

Last Update Posted (Estimated)

December 23, 2025

Last Update Submitted That Met QC Criteria

December 16, 2025

Last Verified

September 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2015_24
  • 2016-A00386-45 (Other Identifier: ID-RCB number, ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk Factor

Subscribe